Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Medtronic

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for TEW-7197


Email this page to a colleague

« Back to Dashboard

What is the drug development status for TEW-7197?

TEW-7197 is an investigational drug.

There have been 12 clinical trials for TEW-7197. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2021.

The most common disease conditions in clinical trials are Adenocarcinoma, Pancreatic Neoplasms, and Stomach Neoplasms. The leading clinical trial sponsors are MedPacto, Inc., AstraZeneca, and Samsung Medical Center.

There are two US patents protecting this investigational drug and thirty-two international patents.

Recent Clinical Trials for TEW-7197
TitleSponsorPhase
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionAstraZenecaPhase 2
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionMedPacto, Inc.Phase 2
As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to BiomarkersSamsung Medical CenterPhase 2

See all TEW-7197 clinical trials

Clinical Trial Summary for TEW-7197

Top disease conditions for TEW-7197
Top clinical trial sponsors for TEW-7197

See all TEW-7197 clinical trials

US Patents for TEW-7197

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TEW-7197 ⤷  Try it Free 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same Frequency Therapeutics, Inc. (Woburn, MA) ⤷  Try it Free
TEW-7197 ⤷  Try it Free Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) PRESIDENT AND FELLOWS OF HARVARD COLLEGE (Cambridge, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TEW-7197

Drugname Country Document Number Estimated Expiration Related US Patent
TEW-7197 European Patent Office EP3313420 2035-06-25 ⤷  Try it Free
TEW-7197 Japan JP2018519298 2035-06-25 ⤷  Try it Free
TEW-7197 World Intellectual Property Organization (WIPO) WO2016210292 2035-06-25 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKesson
Mallinckrodt
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.